Evidence map›Paper›PMID 41624860›Full record

ArticleFrontiers in immunology2025

Intranasal vaccines adjuvanted with Nexavant demonstrate robust protective efficacy by inducing both mucosal and systemic immunity in a murine model.

Kwang Hyun Ko, Hyun Shik Bae, So Min Lee, Somin Park, Seung Hyun Han, Jun Heo, Jinil Kim, Yerim Cho, Dong-Ho Kim, Seung Bin Cha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kwang Hyun KoResearch and Development (R&D) Center, NA Vaccine Institute, Seoul, Republic of Korea.
Hyun Shik BaeResearch and Development (R&D) Center, NA Vaccine Institute, Seoul, Republic of Korea.
So Min LeeResearch and Development (R&D) Center, NA Vaccine Institute, Seoul, Republic of Korea.
Somin ParkDepartment of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Seung Hyun HanDepartment of Oral Microbiology and Immunology, and Dental Research Institute, School of Dentistry, Seoul National University, Seoul, Republic of Korea.
Jun HeoVaccine Research and Development (R&D) Team, Central Institute, Il Yang Pharmaceutical, Yongin, Republic of Korea.
Jinil KimVaccine Research and Development (R&D) Center, Eubiologics Co., Ltd, Chuncheon, Republic of Korea.
Yerim ChoVaccine Research and Development (R&D) Center, Eubiologics Co., Ltd, Chuncheon, Republic of Korea.
Dong-Ho KimResearch and Development (R&D) Center, NA Vaccine Institute, Seoul, Republic of Korea.
Seung Bin ChaResearch and Development (R&D) Center, NA Vaccine Institute, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosal vaccines offer the advantage of inducing immunity at pathogen entry sites; however, concerns about safety and limited efficacy have hindered the widespread use of viral-vectored intranasal vaccines. Nexavant (NVT), a well-defined TLR3 agonist, was investigated as a non-viral mucosal adjuvant. NVT was formulated with commercial subunit and polysaccharide-protein conjugate antigens and administered intranasally to mice. NVT-adjuvanted vaccines elicited robust mucosal IgA and systemic IgG responses, enhanced antigen-specific CD4

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineImmunity, MucosalInfluenza VaccinesOrthomyxoviridae InfectionsAdministration, IntranasalAnimalsAntibodies, ViralDisease Models, AnimalFemaleImmunoglobulin AImmunoglobulin GMiceMice, Inbred C57BLMice, KnockoutReceptor, Interferon alpha-betaAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, ViralIfnar1 protein, mouseImmunoglobulin AImmunoglobulin GInfluenza VaccinesReceptor, Interferon alpha-betaToll-Like Receptor Agonistsintranasal vaccinemucosal immunitysystemic immunityTLR3 agonisttype I interferonvaccine adjuvant

Identifiers

PMID41624860
PMCPMC12855080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.